GSK 586529

Drug Profile

GSK 586529

Alternative Names: 586529; GSK586529

Latest Information Update: 26 Jun 2012

Price : $50

At a glance

  • Originator GlaxoSmithKline; Neurocrine Biosciences
  • Developer GlaxoSmithKline
  • Class Antidepressants; Anxiolytics; Small molecules
  • Mechanism of Action Corticotropin releasing factor receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Depressive disorders

Most Recent Events

  • 26 Jun 2012 Discontinued - Phase-I for Anxiety disorders in USA (PO)
  • 26 Jun 2012 Discontinued - Phase-I for Depressive disorders in USA (PO)
  • 05 Feb 2008 Phase-I clinical trials in Anxiety disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top